Document is current
Any future updates will be listed below
-
Authors
O’Connor, Timothy E.
Lin, Chenyu https://orcid.org/0000-0002-4542-4232
Roloff, Gregory W.
Zhang, Amy
Miller, Katharine
Aldoss, Ibrahim
Kopmar, Noam E.
Dekker, Simone E.
Gupta, Vishal K.
Jeyakumar, Nikeshan
Muhsen, Ibrahim N.
Valtis, Yannis
Ahmed, Naveed
Sutherland, Katherine
Dykes, Kaitlyn C.
Ahmed, Mohamed
Chen, Evan
Zambrano, Hector
Bradshaw, Danielle
Mercadal, Santiago
Schwartz, Marc
Tracy, Sean
Connor, Matthew P. https://orcid.org/0000-0003-1186-0623
Kubiak, Michal
Mukherjee, Akash
Majhail, Navneet https://orcid.org/0000-0001-7082-891X
Battiwalla, Minoo
Mountjoy, Luke
Malik, Shahbaz A.
Mathews, John
Shaughnessy, Paul
Blunk, Betsy
Logan, Aaron C. https://orcid.org/0000-0002-1179-5879
Ladha, Abdullah
Advani, Anjali S. https://orcid.org/0000-0003-0015-5902
Stefan, Maryann
Guzowski, Caitlin
Hoeg, Rasmus T.
Hilal, Talal
Moore, Jozal https://orcid.org/0000-0003-4811-5790
O’Dwyer, Kristen M.
Hill, LaQuisa C. https://orcid.org/0000-0003-4304-935X
Sasine, Joshua https://orcid.org/0000-0001-9866-462X
Oliai, Caspian
Solh, Melhem M. https://orcid.org/0000-0003-3766-5623
Lee, Catherine J. https://orcid.org/0000-0003-2587-8955
Kota, Vamsi K.
Koura, Divya
Kumaran, Muthu V.
Leonard, Jessica T. https://orcid.org/0000-0001-5576-0048
Frey, Noelle V.
Park, Jae H.
Luskin, Marlise R. https://orcid.org/0000-0002-5781-4529
Bachanova, Veronika https://orcid.org/0000-0002-9325-432X
Galal, Ahmed
Pullarkat, Vinod https://orcid.org/0000-0001-9129-3424
Bishop, Michael R.
Stock, Wendy
Cassaday, Ryan D. https://orcid.org/0000-0002-3424-2425
Shah, Bijal D.
Faramand, Rawan
Muffly, Lori S. https://orcid.org/0000-0002-9887-6136
Tsai, Stephanie B.
Dholaria, Bhagirathbhai https://orcid.org/0000-0003-2371-3655
- License Information
-
More Information
Article History
Received: 21 April 2025
Revised: 2 July 2025
Accepted: 4 August 2025
First Online: 23 August 2025
Competing interests
: T.O.: None C.L.: Advisory board/Consultancy: Rigel, Autolus, ADC Therapeutics G.W.R.: Kite/Gilead, Autolus: Advisory board member A.Z.: None K.M.: None I.A.: Consultancy: KiTE, Sobi, Jazz, Pfizer, Amgen, Takeda; Honoraria: Amgen; Advisory board: Amge, Pfizer, Jazz, KiTE, Takeda, Syndax, Sobi, Wugen; Research support: Abbvie, Macrogenics N.E.K.: None S.E.D.: None V.K.G.: None N.J.: None I.N.M.: None Y.V.: None N.A.: None K.S.: Consultancy: OrcaBio K.C.D.: None M.A.: None E.C.: Consultancy: Abbvie H.Z.: None D.B.: None S.M.: None M.S.: Consultancy: Jazz, Novartis S.T.: None M.P.C.: None M.K.: None A.M.: None N.M.: Advisory board: Anthem M.B.: Research funding: Novartis, Fate Therapeutics, L.M.: None S.A.M.: None J.M.: None P.S.: Honoraria: Autolus, BMS; Speakers Bureau: BMS, Sanofi B.B.: None A.C.L.: Research funding: Amgen, Astellas, Autolus, Kadmon, KiTE/Gilead, Pharmcyclics, Talaris; Consultancy: Abbvie, Amgen, Actinium, BMS, Pfizer, Sanofi, Takeda A.L.: Consultancy: Pfizer, CTI Biopharma A.S.A.: Honoraria/Consulting/Advisory Board: Servier, Takeda, Glycomimetics, Pfizer, Novartis, Jazz, KiTE, Amgen; Research funding: OBI, Pfizer, Immunogen/Abbvie, Kura, Glycomimetics, Seattle Genetics/Pfizer, Incyte, Beam, KiTE, Amgen, Servier, Glycomimetics M.S.: None C.G.: None R.T.H.: Research funding: OrcaBio T.H.: Consultancy: BeiGene; Research funding: BeiGene J.M.: None K.M.O.: None L.C.H.: Consultancy: March Biosciences; Speaker: KiTE/Gilead J.S.: None C.O.: Research funding: Novartis, Arog, Orca Bio, Jazz, Pfizer, Seagen M.M.S.: Speakers bureau: Bristol-Myers Squibb C.J.L.: Consultancy: Fresenius Kabi, Sanofi, Incyte Corp; Honoraria: KiTE, BMS, Sanofi, Kadmon; Advisory board: KiTE, Sanofi, Incyte Corp; Speakers bureau: KiTE; Research funding: Incyte corp V.K.K.: Honoraria: KiTE, Novartis, Pfizer; Research funding: Incyte corp D.K.: Consultancy: BMS; Research funding: BMSM.V.: None J.T.L.: Consultancy: Adaptive Biotechnologies, Pfizer, KiTE/Gilead, Takeda; Advisory board: Adaptive Biotechnologies N.V.F.: None J.H.P.: None M.R.L.: None V.B.: Advisory board: Astra Zeneca, Allogene, BeiGene, CRISPR; DSMB Board: Miltenyi; Research funding: Citius, Incyte corp A.G.: None V.P.: Consultancy: Servier, Amgen, Pfizer, Jazz, Novartis, Genentech, Abbvie; Speakers bureau: Servier, Amgen, Pfizer, Jazz, Novartis, Genentech, Abbvie M.R.B.: Consultancy/Advisory board: KiTE/Gilead, Novartis, Bristol Myers Squibb, CRISPR, Autlus, In8bio, Sana Biotechnology, Chimeric Therapeutics, Arcellx, Achieve Clinics; Honoraria: Bristol Myers Squibb, KiTE/Gilead, Novartis, Incyte, Servier, Sanofi, ADC Therapeutics W.S.: None R.D.C.: Research funding: Servier, Incyte corp, KiTE/Gilead, Amgen, Vanda Pharmaceuticals, Jazz, Merck, Pfizer; Advisory board: PeproMene Bio, Autolus; Consultancy/Honoraria: KiTE/Gilead, Amgen, Jazz, Pfizer; Other: Spouse employed by and owned stock in Seagen within past 24 months B.D.S.: Research funding: Incyte, Jazz, KiTE/Gilead, Servier; Honoraria: Pharmacyclics/Janssen, Spectrum/Acrotech, BeiGene, Gilead Sciences; Other: Travel, accomodations, expenses: KiTE/Gilead, Stemline Therapeutics, AstraZeneca, Seattle Genetics, Janssen, Pfizer, Novartis, Celgene; Advisory board: DSMC, Pepromene Bio; Consultancy: Takeda, AstraZeneca, Adaptive Biotechnologies, BMS/Celgene, Novartis, Pfizer, Amgen, Precision Biosciences, KiTE/Gilead, Jazz, Century Therapeutics, Deciphera, Autolus, Lilly, Pepromene R.F.: Research funding: KiTE/Gilead, Novartis; Advisory board: KiTE/Gilead L.S.M.: Consultancy: Amgen, Pfizer, Kite, Autolus, Astellas; Research funding: BMS, Adaptive, Kite, Astellas, Orca Bio, Jasper; Advisory board: Adaptive ST: Advisory board/Consultancy: Jazz, BMS, Sanofi BD: Institutional research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir, Adicet, BMS, Molecular template, Atara. Consultancy/Advisor: MJH BioScience, Arivan Research, Janssen, ADC therapeutics, Gilead, GSK, Caribou, Roche, Autolus Permission to reproduce material from other sources: All work within, including, tables and figures within are original to the authors.
